Genmab — April 2018
-
"Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment " Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment - http://www.mrknewsroom.com/news-release/oncology/incyte-and-merck-provide-update-phase-3-study-epacadostat-0
-
Hardly. I don't think there are any studies og dara in melanoma ongoing. So not in this particular indication. But epacadostat is being tested with nivolumab in different solid cancers. Thus competition might arise in other indications. https://en.wikipedia.org/wiki/Epacadostat https://www.clinicaltrials.gov/ct2/results?cond=&term=nivolumab+epacadostat&cntry=&state=&city=&dist=&Search=Search
-
Ellers noget af et program, de har kørende, Incyte. Hele 26 kombistudier med pembro, heraf flere store fase 3 studier. I alskens solide tumorer. De fleste sponseret af dem selv. https://www.clinicaltrials.gov/ct2/results?cond=&term=epacadostat+pembrolizumab&cntry=&state=&city=&dist=
-
G0d morgen.
-
Meget afdæmpet effekt af et positivt c25 på Genmab aktien?
-
Danske Bank har kommenteret på det negative udfald af Incyte/Merck studier i melanoma. De mener ikke der er den store sammenhæng til dara i solide. Dog kan det generelt m
edføre en større skepsis i markedet til positive fase 2 data.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind